Success Metrics

Active Trials
4(80%)

Phase Distribution

Ph phase_2
3
60%
Ph early_phase_1
1
20%
Ph phase_1
1
20%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Active, not recruiting2
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 23 (60.0%)

Trials by Status

active_not_recruiting240%
recruiting240%
withdrawn120%

Recent Activity

4 active trials
Showing 5 of 5
recruitingearly_phase_1

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

NCT04975217
active_not_recruitingphase_2

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT06026371
active_not_recruitingphase_2

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

NCT04729322
recruitingphase_2

Fecal Microbiota Transplantation for Radiation-Induced Proctopathy

NCT06776029
withdrawnphase_1

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

NCT04280471

Clinical Trials (5)

Showing 5 of 5 trials
NCT04975217Early Phase 1

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Recruiting
NCT06026371Phase 2

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Active Not Recruiting
NCT04729322Phase 2

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Active Not Recruiting
NCT06776029Phase 2

Fecal Microbiota Transplantation for Radiation-Induced Proctopathy

Recruiting
NCT04280471Phase 1

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5